SS-31: Molecular Characterization and Lipid-Binding Interactions — A Research Reference

The sequence is D-arginine, 2,6-dimethyltyrosine, lysine, phenylalanine, with an amidated carboxyl terminus — written D-Arg-Dmt-Lys-Phe-NH2. It weighs approximately 640 daltons.

The design principle is visible in the ordering. Positions one and three are basic residues, arginine and lysine, each carrying a positively charged side chain at neutral pH. Positions two and four are aromatic, dimethyltyrosine and phenylalanine. The chain therefore alternates basic, aromatic, basic, aromatic — a motif shared across the numbered SS series and varied systematically within it [1]. Together with the amidated terminus, which removes the negative charge a free carboxylate would carry, the peptide holds a net charge near +3 across only four residues.

Two residues resist enzymatic breakdown. The arginine is present in the D configuration rather than the natural L form, and proteases have evolved to act on L-amino acid sequences. The dimethyltyrosine is a tyrosine bearing two methyl groups on its aromatic ring — a non-proteinogenic residue no natural enzyme is shaped to process.

The characterized interaction is with cardiolipin, a phospholipid distinctive to the inner mitochondrial membrane. Reported in-vitro work established that the peptide associates with cardiolipin-containing membranes and that this association, rather than engagement of a protein receptor, is the molecular event underlying its behaviour in mitochondrial preparations [2].

Subsequent biophysical work characterized the interaction directly in defined lipid systems rather than in organelles. Binding to lipid bilayers was measured, and the peptide was shown to modulate the surface electrostatics of the membrane it associates with — a consequence of concentrating a +3 charge at the bilayer surface, and a property that follows directly from the alternating basic-aromatic architecture described above [3]. The aromatic residues partition into the interfacial region while the basic side chains remain in contact with the anionic lipid headgroups.

The distinction from receptor pharmacology matters for experimental design. There is no binding pocket, no G-protein coupling, and no downstream transducer to assay; the relevant measurements are partition coefficients, bilayer binding constants, and electrostatic surface potential. Membrane composition — the proportion of anionic lipid in particular — is the dominant experimental variable, in the way receptor subtype is for a GPCR ligand.

Mass spectrometry confirms the intact molecular mass near 640 daltons. The measurement also confirms the amidated terminus: a free-acid impurity, where the amide failed to form during synthesis, is heavier by approximately one dalton, a defined difference detectable at adequate resolving power.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. The characteristic related substance is the diastereomer — the D-arginine at position one can invert to the L form during synthesis, producing a compound of identical molecular mass that mass spectrometry cannot distinguish at all. It separates chromatographically, which is why the two methods are run together rather than either treated as sufficient.

Incomplete methylation is a second, compound-specific consideration. Dimethyltyrosine is not a stock reagent in the way ordinary amino acids are, and a peptide carrying plain tyrosine in its place is lighter by a defined increment — a mass question with a defined answer, and one worth asking of any batch.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided.

The high net positive charge makes the peptide readily water-soluble, and at four residues it presents essentially no surface for aggregation. That same charge has a handling consequence: strongly cationic peptides adsorb to negatively charged surfaces, including some glass and untreated plastics, so low-binding labware is a reasonable default where small quantities are being measured. The effect is not incidental here — the molecule's defining property is affinity for anionic surfaces, and a labware surface is one.

By composition the peptide is otherwise robust: no cysteine or methionine removes the common oxidation routes, and no asparagine or glutamine removes deamidation. The residues warranting attention are the two aromatics, phenolic side chains of the tyrosine class being susceptible to oxidation under harsh conditions and to light over extended periods.

SS-31 is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade SS-31 is accompanied by an independent certificate of analysis specific to that lot.

SS-31 is a tetrapeptide of approximately 640 daltons — D-Arg-Dmt-Lys-Phe-NH2 — built on an alternating basic-aromatic motif that concentrates a net charge near +3 on a four-residue chain. Its characterized in-vitro interaction is with cardiolipin-containing membranes rather than with a protein receptor, and biophysical work in defined lipid systems established both bilayer binding and modulation of membrane surface electrostatics. Analytical verification rests on mass confirmation of the amidated terminus and the dimethylated aromatic residue, chromatographic resolution of a mass-identical diastereomer, and batch-specific net peptide content.